Your browser doesn't support javascript.
loading
Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma.
Harada, Ken-Ichi; Miyake, Hideaki; Furukawa, Junya; Fujimoto, Naohiro; Fujisawa, Masato.
Affiliation
  • Harada KI; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Miyake H; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Furukawa J; Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Fujimoto N; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Fujisawa M; Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Int J Urol ; 29(8): 816-822, 2022 08.
Article in En | MEDLINE | ID: mdl-35636920
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Humans Language: En Journal: Int J Urol Journal subject: UROLOGIA Year: 2022 Type: Article Affiliation country: Japan
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms / Antineoplastic Agents Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Humans Language: En Journal: Int J Urol Journal subject: UROLOGIA Year: 2022 Type: Article Affiliation country: Japan